- Home
- HURA vs ALAR Comparison
HURA vs ALAR Comparison
Compare HURA & ALAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HURA
- ALAR
- Stock Information
- Founded
- HURA 2009
- ALAR 2013
- Country
- HURA United States
- ALAR Israel
- Employees
- HURA N/A
- ALAR N/A
- Industry
- HURA
- ALAR Computer Software: Prepackaged Software
- Sector
- HURA
- ALAR Technology
- Exchange
- HURA Nasdaq
- ALAR Nasdaq
- Market Cap
- HURA 103.3M
- ALAR 98.9M
- IPO Year
- HURA N/A
- ALAR 2018
- Fundamental
- Price
- HURA $2.64
- ALAR $11.85
- Analyst Decision
- HURA Strong Buy
- ALAR Strong Buy
- Analyst Count
- HURA 2
- ALAR 1
- Target Price
- HURA $11.50
- ALAR $15.00
- AVG Volume (30 Days)
- HURA 500.9K
- ALAR 151.3K
- Earning Date
- HURA 08-15-2025
- ALAR 08-25-2025
- Dividend Yield
- HURA N/A
- ALAR N/A
- EPS Growth
- HURA N/A
- ALAR N/A
- EPS
- HURA N/A
- ALAR 0.07
- Revenue
- HURA N/A
- ALAR $30,581,000.00
- Revenue This Year
- HURA N/A
- ALAR N/A
- Revenue Next Year
- HURA $69.15
- ALAR $12.28
- P/E Ratio
- HURA N/A
- ALAR $18.13
- Revenue Growth
- HURA N/A
- ALAR 4.67
- 52 Week Low
- HURA $1.80
- ALAR $5.45
- 52 Week High
- HURA $9.94
- ALAR $30.20
- Technical
- Relative Strength Index (RSI)
- HURA N/A
- ALAR 52.06
- Support Level
- HURA N/A
- ALAR $11.61
- Resistance Level
- HURA N/A
- ALAR $12.50
- Average True Range (ATR)
- HURA 0.00
- ALAR 0.69
- MACD
- HURA 0.00
- ALAR -0.34
- Stochastic Oscillator
- HURA 0.00
- ALAR 18.52
About HURA TuHURA Biosciences Inc. Common Stock
TuHURA Biosciences Inc is a Phase 3 registration stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. It is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda (pembrolizumab) in first-line treatment for advanced or metastatic Merkel Cell Carcinoma.
About ALAR Alarum Technologies Ltd.
Alarum Technologies Ltd is a software-as-a-service (SaaS) provider operating mainly in the web data collection market, offering web data collection and a private internet browsing platform. The company's Web Data Collection products offer secure, fast, and anonymous IP Proxy Network Solutions & Services, or IPPN or IPPN Solutions, to its business customers which, in turn, enables them to anonymously and securely browse the internet as well as to collect data from any publicly available source on the web, for their business purpose. The company operates in one segment, which is web data collection. Geographically, it derives maximum revenue from United Arab Emirates, followed by China, the United States, Europe, Asia-Pacific, U.K. Virgin Islands, Middle East and Africa, and other regions.